Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Income from Continuing Operations (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Income from Continuing Operations for 11 consecutive years, with 62530000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 11.07% year-over-year to 62530000.0, compared with a TTM value of 155203000.0 through Dec 2025, up 25.39%, and an annual FY2025 reading of 155203000.0, up 25.39% over the prior year.
  • Income from Continuing Operations was 62530000.0 for Q4 2025 at Spyre Therapeutics, down from 11183000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 6738000.0 in Q2 2021 and bottomed at 217081000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 42573900.0, with a median of 30576500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 872.45% in 2023, then soared 83.8% in 2025.
  • Year by year, Income from Continuing Operations stood at 20446000.0 in 2021, then increased by 8.07% to 18796000.0 in 2022, then crashed by 236.14% to 63180000.0 in 2023, then grew by 10.9% to 56296000.0 in 2024, then dropped by 11.07% to 62530000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SYRE at 62530000.0 in Q4 2025, 11183000.0 in Q3 2025, and 36717000.0 in Q2 2025.